| Reference |
Sentence |
Publish Date |
Extraction Date |
Species |
| Erica Braun, Francesca M Gualano, Prabha Siddarth, Eric Sega. Second-line cannabis therapy in patients with epilepsy. Clinical neurology and neurosurgery vol 227 issue 2023 36870086 |
second-line cannabis therapy in patients with epilepsy. |
2023-03-04 |
2023-03-06 |
Not clear |
| Antonella Riva, Gianluca D'Onofrio, Angelica Pisati, Roberta Roberti, Elisabetta Amadori, Friedrich Bosch, Carolina Fischinger Moura de Souza, Ashley Thomas, Emilio Russo, Pasquale Striano, Allan Baya. Cannabidiol Add-On in Glycosylphosphatidylinositol-Related Drug-Resistant Epilepsy. Cannabis and cannabinoid research vol issue 2023 36862522 |
cannabidiol add-on in glycosylphosphatidylinositol-related drug-resistant epilepsy. |
2023-03-02 |
2023-03-06 |
Not clear |
| Se Hee Kim, Han Som Choi, Chung Mo Koo, Bong-Rim Joo, Byung-Joo Park, Hae Kook Lee, Joon Soo Lee, Heung Dong Kim, Hoon-Chul Kan. Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy. Journal of clinical neurology (Seoul, Korea) vol 19 issue 2 2023 36854341 |
erratum: effects of cannabidiol on adaptive behavior and quality of life in pediatric patients with treatment-resistant epilepsy. |
2023-02-28 |
2023-03-06 |
Not clear |
| George J\\xc3\\xaetc\\xc4\\x83, Bianca E \\xc5\\x90sz, Camil E Vari, Carmen-Maria Rusz, Amelia Tero-Vescan, Amalia Pu\\xc8\\x99ca\\xc8\\x9. Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance. Antioxidants (Basel, Switzerland) vol 12 issue 2 2023 36830042 |
the literature provides scientific evidence for the beneficial effects of cannabidiol (cbd), and these effects extend beyond epilepsy treatment (e.g., lennox-gastaut and dravet syndromes), notably the influence on oxidative status, neurodegeneration, cellular protection, cognitive function, and physical performance. |
2023-02-25 |
2023-03-06 |
Not clear |
| Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one vol 18 issue 1 2023 36706124 |
cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: single tertiary referral center survey investigation. |
2023-01-27 |
2023-01-31 |
Not clear |
| Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one vol 18 issue 1 2023 36706124 |
this study sought to identify differences in cannabis use and perceptions about cannabis in mitigating seizure-related symptoms in patients with epilepsy, and to evaluate differences in these patterns between drug-resistant versus pharmacoresponsive epilepsy. |
2023-01-27 |
2023-01-31 |
Not clear |
| Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one vol 18 issue 1 2023 36706124 |
a collection of self-report surveys completed by patients with epilepsy (n = 76) were used to retrospectively compare differences in those with drug-resistant versus pharmacoresponsive epilepsy regarding 1) proportion who used cannabis, 2) frequency of use, 3) method of use, and 4) reason for use. |
2023-01-27 |
2023-01-31 |
Not clear |
| Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one vol 18 issue 1 2023 36706124 |
results from this study highlight the need for epilepsy providers to formally assess patients' perceptions and use of non-prescribed cannabis to inform clinical care decisions, particularly in the drug-resistant epilepsy population. |
2023-01-27 |
2023-01-31 |
Not clear |
| Lyndsey L Anderson, Dilara A Bahceci, Nicole A Hawkins, Declan Everett-Morgan, Samuel D Banister, Jennifer A Kearney, Jonathon C Arnol. Heterozygous deletion of Gpr55 does not affect a hyperthermia-induced seizure, spontaneous seizures or survival in the Scn1a+/- mouse model of Dravet syndrome. PloS one vol 18 issue 1 2023 36701411 |
a purified preparation of cannabidiol (cbd), a cannabis constituent, has been approved for the treatment of intractable childhood epilepsies such as dravet syndrome. |
2023-01-26 |
2023-01-31 |
mouse |
| Fabienne K\\xc3\\xbchne, Lena-Luise Becker, Thomas Bast, Astrid Bertsche, Ingo Borggraefe, Christian Malte Bo\\xc3\\x9felmann, J\\xc3\\xb6rg Fahrbach, Christoph Hertzberg, Nina A Herz, Martin Hirsch, Martin Holtkamp, Christine Janello, Gerhard Josef Kluger, Gerhard Kurlemann, Holger Lerche, Konstantin L Makridis, Felix von Podewils, Milka Pringsheim, Susanne Schubert-Bast, Juliane Schulz, Andreas Schulze-Bonhage, David Steinbart, Bernhard J Steinhoff, Adam Strzelczyk, Steffen Syrbe, Heike De Vries, Christiane Wagner, Johanna Wagner, Bernd Wilken, Christine Prager, Kerstin A Klotz, Angela M Kaind. Real world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study. Epilepsia open vol issue 2023 36693811 |
real world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study. |
2023-01-24 |
2023-01-31 |
Not clear |
| Cindy H T Yeung, Jessica L Beers, Klarissa D Jackson, Andrea N Edginto. Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically based pharmacokinetic modelling. CPT: pharmacometrics & systems pharmacology vol issue 2022 36540909 |
cannabidiol (cbd) is approved for treatment of seizures associated with two forms of epilepsy that become apparent in infancy or early childhood. |
2022-12-21 |
2023-01-30 |
human |
| Jerzy P Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D Park, Pilar Pichon Zentil, Anup D Patel, Elizabeth A Thiele, Robert T Wechsler, Daniel Checketts, Farhad Sahebka. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: 4-year results from the expanded access program. Epilepsia vol issue 2022 36537757 |
long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: 4-year results from the expanded access program. |
2022-12-20 |
2023-01-30 |
Not clear |
| Jerzy P Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D Park, Pilar Pichon Zentil, Anup D Patel, Elizabeth A Thiele, Robert T Wechsler, Daniel Checketts, Farhad Sahebka. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: 4-year results from the expanded access program. Epilepsia vol issue 2022 36537757 |
cannabidiol (cbd) expanded access program (eap), initiated in 2014, provided add-on cbd to patients with treatment-resistant epilepsy (tre) at 35 us epilepsy centers. |
2022-12-20 |
2023-01-30 |
Not clear |
| Simon Erridge, Carl Holvey, Ross Coomber, Jonathan Hoare, Shaheen Khan, Michael Platt, James Rucker, Mark Weatherall, Sushil Beri, Mikael Sodergre. Clinical Outcome Data of Children Treated with Cannabis Based Medicinal Products for Treatment Resistant Epilepsy - Analysis from the UK Medical Cannabis Registry. Neuropediatrics vol issue 2022 36539215 |
clinical outcome data of children treated with cannabis based medicinal products for treatment resistant epilepsy - analysis from the uk medical cannabis registry. |
2022-12-20 |
2023-01-30 |
Not clear |
| Hakan Silek, Ozgur Bilgin Topcuogl. Analysis of YouTube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. Epilepsy & behavior : E&B vol 138 issue 2022 36473301 |
analysis of youtube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. |
2022-12-15 |
2023-01-30 |
Not clear |
| Hakan Silek, Ozgur Bilgin Topcuogl. Analysis of YouTube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. Epilepsy & behavior : E&B vol 138 issue 2022 36473301 |
cannabidiol (cbd) oil has been used for the treatment of refractory epilepsy for a long time. |
2022-12-15 |
2023-01-30 |
Not clear |
| Lindsay F Smegal, Pooja Vedmurthy, Matthew Ryan, Melissa Eagen, Nicole Whiston Andrejow, Kristie Sweeney, Teressa Garcia Reidy, SangEun Yeom, Doris D Lin, Stacy J Suskauer, Luther G Kalb, Jay A Salpekar, T Andrew Zabel, Anne M Com. Cannabidiol Treatment for Neurological, Cognitive, and Psychiatric Symptoms in Sturge-Weber Syndrome. Pediatric neurology vol 139 issue 2022 36508880 |
a prior drug trial of cannabidiol for treatment-resistant epilepsy in patients with sturge-weber syndrome (sws), a rare neurovascular condition, implicated improvements in neurological, quality of life (qol), neuropsychologic, psychiatric, and motor outcomes. |
2022-12-12 |
2023-01-30 |
Not clear |
| Victoria Golub, Sreevidhya Ramakrishnan, Doodipala Samba Redd. Isobolographic analysis of adjunct Antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. Experimental neurology vol issue 2022 36493860 |
isobolographic analysis of adjunct antiseizure activity of the fda-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. |
2022-12-09 |
2023-01-30 |
Not clear |
| Victoria Golub, Sreevidhya Ramakrishnan, Doodipala Samba Redd. Isobolographic analysis of adjunct Antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. Experimental neurology vol issue 2022 36493860 |
cannabidiol (cbd) has been shown to decrease seizures in pediatric epilepsies, such as dravet and lennox-gastaut syndromes; however, it has not been rigorously tested for adult seizures or in models of refractory focal epilepsy. |
2022-12-09 |
2023-01-30 |
Not clear |
| Aaron Del Pozo, Melissa Barker-Halisk. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Experimental neurology vol 360 issue 2022 36471511 |
cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. |
2022-12-06 |
2023-01-30 |
Not clear |